Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices.

Abbott Laboratories showed strong performance in Q2 2026 with a 4.8% year-over-year sales increase and a 100 basis point rise in adjusted gross margin to 58.0%. Growth was fueled by its acquisition of Exact Sciences for cancer diagnostics, innovative electrophysiology solutions, and a turnaround in its nutrition segment. Despite a valuation-driven downgrade from "Strong Buy" to "Buy," the company is expected to deliver low-teens annual total returns supported by solid fundamentals. Abbott remains a diversified healthcare leader with momentum across key business areas.